Hikal Reports ₹4.48 Billion Revenue, ₹172 Million Profit in Q3 FY24

Hikal Ltd. reported consolidated revenue of ₹4.48 billion for the December quarter, reflecting stable growth in its pharmaceutical and crop protection segments. The company’s net profit stood at ₹172 million, marking a steady financial performance despite industry challenges.

The pharmaceutical division contributed significantly to revenue, while the crop protection segment remained resilient despite volatile raw material prices. Analysts expect Hikal’s focus on research-driven solutions and cost optimization to drive future profitability. Investors are watching upcoming product launches and global demand trends for further insights.

Source: Business Pharma Insights